Brands: Saxenda · Liraglutide
Average across 6 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Orbicular Pharmaceutical Technologies Private Limited | unknown | 4 | SUPPLYING |
| Cipla USA Inc. | generic | 4 | SUPPLYING |
| Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | unknown | 3 | SUPPLYING |
| Novo Nordisk | unknown | 3 | SUPPLYING |
| Biocon Pharma Inc, | unknown | 2 | SUPPLYING |
| A-S Medication Solutions | repackager | 1 | SUPPLYING |
| Teva Pharmaceuticals USA, Inc. | generic | 1 | EXITED 2027 |
Shortages, recalls, and registration changes attached to this drug concept.
Liraglutide Injection — reported in shortage by Teva Pharmaceuticals USA, Inc.. Therapeutic category: Endocrinology/Metabolism.
Liraglutide Injection — reported in shortage by Teva Pharmaceuticals USA, Inc.. Therapeutic category: Endocrinology/Metabolism.
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. — Recalling firm: Novo Nordisk Inc — Nationwide in the USA
